In advanced CRC, Rituximab, a humanized monoclonal antibody targeting human being CD20, apparently reduced the tumor burden (153)
In advanced CRC, Rituximab, a humanized monoclonal antibody targeting human being CD20, apparently reduced the tumor burden (153). assisting its use. 0.001) was favorable prognostic… Read More »In advanced CRC, Rituximab, a humanized monoclonal antibody targeting human being CD20, apparently reduced the tumor burden (153)